

ADMA BIOLOGICS, INC.  
Form 8-K  
June 24, 2015

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 24, 2015

ADMA BIOLOGICS, INC.  
(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)	001-36728 (Commission File Number)	56-2590442 (IRS Employer Identification No.)
465 State Route 17 Ramsey, New Jersey (Address of principal executive offices)		07446 (Zip Code)

Registrant's telephone number, including area code: (201) 478-5552

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item Regulation FD.  
7.01.

Members of the management team of ADMA Biologics, Inc. (the "Company") plan to make a presentation at the JMP Securities Life Sciences Conference at 2:00 PM ET on June 24, 2015, in New York, NY. A copy of the slide presentation that the Company intends to use is furnished as Exhibit 99.1 to this Current Report on Form 8-K. A live webcast of the presentation may be accessed under the "Investor Relations" tab on the Company's website at [www.admabiologics.com](http://www.admabiologics.com). A replay of the webcast will be available after the conclusion of the live event.

In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1 hereto (which has been furnished solely for this Item 7.01 and Exhibit 99.1), shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item Financial Statements and Exhibits.  
9.01.  
(d) Exhibits

Exhibit Description  
No.

99.1 Slide Presentation dated June 24, 2015.

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

June 24, 2015

ADMA Biologics, Inc.

By: /s/ Brian Lenz  
Name: Brian Lenz  
Title: Chief Financial Officer

---

Exhibit Index

Exhibit No.	Description
-------------	-------------

99.1	Slide Presentation dated June 2015.
------	-------------------------------------